TABLE 2.
Clinical and tumor characteristics by surgery type
| Characteristics | Lumpectomy (N = 365) n (%) |
Mastectomy (N = 258) n (%) |
p value |
|---|---|---|---|
| Menopausal status | <0.001 | ||
| Pre | 88 (24.1) | 115 (44.6) | |
| Post | 277 (75.9) | 143 (55.4) | |
| BMI (kg/m2) | 0.001 | ||
| <24.9 | 95 (26.0) | 107 (41.5) | |
| 25.0–29.9 | 117 (32.1) | 61 (23.6) | |
| ≥30.0 | 149 (40.8) | 87 (33.7) | |
| Unknown | 4 (1.1) | 3 (1.2) | |
| Comorbidity count | 0.006 | ||
| 0 | 66 (18.1) | 75 (29.1) | |
| 1 | 105 (28.8) | 64 (24.8) | |
| ≥2 | 194 (53.2) | 119 (46.1) | |
| Tumor grade | 0.064 | ||
| Well differentiated | 81 (22.2) | 36 (14.0) | |
| Moderately differentiated | 147 (40.3) | 108 (41.9) | |
| Poorly differentiated | 120 (32.9) | 99 (38.4) | |
| Unknown | 17 (4.7) | 15 (5.8) | |
| Tumor size (cm) | <0.001 | ||
| ≤0.5 | 44 (12.1) | 49 (19.0) | |
| >0.5 to ≤1.0 | 99 (27.1) | 34 (13.2) | |
| >1.0 to ≤2.0 | 134 (36.7) | 70 (27.1) | |
| >2.0 | 88 (24.1) | 105 (40.7) | |
| Node status | <0.001 | ||
| Negative | 293 (80.3) | 165 (64.0) | |
| Positive | 68 (18.6) | 91 (35.3) | |
| Unknown | 4 (1.1) | 2 (0.8) | |
| AJCC stage | <0.001 | ||
| Stage I | 237 (64.9) | 109 (42.2) | |
| Stage II and above | 124 (34.0) | 145 (56.2) | |
| Unknown | 4 (1.1) | 4 (1.6) | |
| ER/PR status | 0.388 | ||
| One positive | 45 (12.3) | 30 (11.6) | |
| Both positive | 245 (67.1) | 170 (65.9) | |
| Both negative | 75 (20.5) | 56 (21.7) | |
| Unknown | 0 (0.0) | 2 (0.8) | |
| HER2 status | 0.019 | ||
| Positive | 52 (14.2) | 53 (20.5) | |
| Negative | 304 (83.3) | 192 (74.4) | |
| Unknown | 9 (2.5) | 13 (5.0) | |
| Triple-negative status | 0.199 | ||
| Yes | 51 (14.0) | 39 (15.1) | |
| No | 305 (83.6) | 206 (79.8) | |
| Unknown | 9 (2.5) | 13 (5.0) | |
| Radiation therapy | <0.001 | ||
| Yes | 356 (97.5) | 53 (20.5) | |
| No | 7 (1.9) | 205 (79.5) | |
| Unknown | 2 (0.5) | 0 (0.0) |
p values are derived from Chi square test
BMI body mass index, AJCC American Joint Committee on Cancer, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2